Company intelligence / Profile preview
AVM Biotechnology
Seattle, Washington, United Statesavmbiotech.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Preclinical
01
Overview
AVM Biotechnology has advanced its lead product AVM0703 into pivotal Phase 2 clinical trials for relapsed/refractory Non-Hodgkin’s Lymphoma and leukemia. The drug has shown promising safety and efficacy signals in both clinical trial participants and expanded access/compassionate use cases across multiple cancer types. Over twenty-eight patients with solid tumors or blood cancers have been treated under these programs with good tolerability reported. The company also holds INDs for ARDS related to viral infections such as COVID‑19[6][7][10].
- Therapeutic areas
- OncologyPulmonologyImmunology
- Modalities
- Small molecule (high-dose dexamethasone formulation)Cell therapy (mobilization of endogenous immune cells)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
National Cancer Institute / NIH SBIR grants[4][6]No major pharma partnerships disclosed as of current data.
Beyond the preview
Go deeper on AVM Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVM Biotechnology.